Study to Evaluate the Effect of Different Pre-seasonal BM32 Dosing Schedules on the Rapid Induction of a Protective IgG Immune Response

Trial Profile

Study to Evaluate the Effect of Different Pre-seasonal BM32 Dosing Schedules on the Rapid Induction of a Protective IgG Immune Response

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Feb 2017

At a glance

  • Drugs Grass pollen allergy immunotherapy (Primary)
  • Indications Hypersensitivity
  • Focus Pharmacodynamics
  • Sponsors Biomay
  • Most Recent Events

    • 26 Jan 2017 Results published in the Biomay media release.
    • 26 Jan 2017 Primary endpoint (Titer of allergen specific IgG4 antibodies) has been met, according to Biomay media release.
    • 18 Jan 2017 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top